Migraine - KOL Insight

Description

Why do many KOLs prefer Teva's Ajovy or Lilly's Emgality over Amgen/Novartis' Aimovig for the preventive management of migraine? Over the next five years, neurologists anticipate subcutaneous anti-CGRP mAbs will challenge Botox as the first-line treatment for migraine prevention, but that use of Lundbeck's Vyepti will remain limited - why? KOLs critically assess the prospects of launched and pipeline therapies.

Key questions answered:

How do KOLs assess the potential impact of Xeomin, Dysport and prabotulinumtoxinA on the use of AbbVie's well-established Botox?
Why are experts impressed by AbbVie's Botox+ Qulipta/Aquipta combination trial?
How do KOLs prescribe Pfizer's Nurtec ODT/Vydura, and what other studies do experts recommend?
What underpins neurologists' opinion that AbbVie's Qulipta/Aquipta is preferable to Pfizer's Nurtec ODT in the preventive management of migraine?
Why do neurologists say that despite being an effective treatment, Lilly's lasmiditan is currently reserved for later-line therapy?
Why are KOLs not particularly impressed by the clinical data for Pfizer's Zavzpret?

Key brands covered in this report:

Botox
Aimovig
Ajovy
Emgality
Reyvow/Rayvow

Ubrelvy
Nurtec ODT/Vydura
Qulipta/Aquipta
Vyepti
Zavzpret

Executive summary (6)

Current and future treatment algorithm

Research objectives (3)

Marketed therapies (137)

Botox (onabotulinum toxin A; AbbVie) (18)
- Key insights summary (18)
Aimovig (erenumab/erenumab-aooe; Amgen/Novartis) (10)
- Key insights summary (10)
Ajovy (fremanezumab/fremanezumab-vfrm; Teva) (10)
- Key insights summary (10)
Emgality (galcanezumab/galcanezumab-gnlm; Lilly) (10)
- Key insights summary (10)
Reyvow/Rayvow (lasmiditan; Lilly) (14)
- Key insights summary (14)
Ubrelvy (ubrogepant; AbbVie) (9)
- Key insights summary (9)
Nurtec ODT/Vydura (rimegepant; Pfizer) (16)
- Key insights summary (16)
Qulipta/Aquipta (atogepant; AbbVie) (16)
- Key insights summary (16)
Vyepti (eptinezumab; Lundbeck) (21)
- Key insights summary (21)
Zavzpret (zavegepant; Pfizer) (13)
- Key insights summary (13)

Early-stage development programmes (22)

Key insights summary (22)
- KOLs are pleased with the Phase II HOPE trial and are enthusiastic about the potential of PACAP therapy in migraine treatment (20)

Current dynamics of oral gepants and subcutaneous anti-CGRP mAbs (12)

Key insights summary (12)
- Better tolerability profile of oral gepants makes them the preferred option over triptans: some KOLs favour subcutaneous mAbs over oral gepants due to adherence issues (10)

Future Outlook for the Migraine Therapies (10)

Key insights summary (10)
- Neurologists foresee triptans to remain a standard choice for acute migraine, with gepants being the second line of treatment (8)

Appendix (4)

KOL details (4)